Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service skin substitutes & wound grafts cases in Pennsylvania: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (246 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 26 | 8,571 | 47% |
| 2020 | 25 | 8,008 | 49% |
| 2021 | 35 | 9,824 | 51% |
| 2022 | 28 | 9,605 | 53% |
| 2023 | 23 | 9,102 | 56% |
| 2024 | 30 | 9,758 | 58% |
| 2025 from claims | – | 11,369 10,434–12,028 | 59% |
| 2026 forecast | – | 11,777 10,362–13,591 | 59% |
| 2027 forecast | – | 12,126 10,366–14,450 | 59% |
| 2028 forecast | – | 12,483 10,416–15,285 | 60% |
| 2029 forecast | – | 12,849 10,495–16,114 | 60% |
| 2030 forecast | – | 13,224 10,594–16,947 | 61% |
Application of cellular and tissue-based products to wounds; the loudest category in Open Payments. Professional codes (what the surgeon bills): CPT 15271, 15273, 15275, 15277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 57% of the cases CMS names in Pennsylvania; 18 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 1% inpatient hospital, 24% hospital outpatient, 75% office. The share outside the hospital has moved +25 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~11,800 | ~120 | ~2,700 | ~9,000 |
| 2027 · ~12,100 | ~130 | ~2,700 | ~9,300 |
| 2028 · ~12,500 | ~130 | ~2,700 | ~9,600 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 22% (24% in 2025), office about 77% (75% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 70 | 14,481+3.3%/yr | +3.3%/yr | 4.7 | 45% | 20,500 in 2030+5.9%/yr |
| New Jersey | 47 | 11,826+17%/yr | +17%/yr | 7.7 | 65% | 21,200 in 2030+10%/yr |
| Massachusetts | 33 | 6,154+1.6%/yr | +1.6%/yr | 4.7 | 36% | 6,700 in 2030+1.4%/yr |
| Connecticut | 15 | 3,005+7.9%/yr | +7.9%/yr | 5.3 | 50% | 4,060 in 2030+5.1%/yr |
| New Hampshire | 12 | 1,375+11%/yr | +11%/yr | 4.4 | 20% | 1,740 in 2030+4%/yr |
| Rhode Island | 3 | 886−5.4%/yr | −5.4%/yr | 5.2 | 41% | 870 in 2030−0.4%/yr |
| Maine | 4 | 721−5.3%/yr | −5.3%/yr | 2.6 | 14% | 740 in 2030+0.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 643 | 120,771−1.4%/yr | −1.4%/yr | 84.30.9× | 52% | 123,700 in 2030+0.4%/yr |
| Bone graft & orthobiologics | 25 | 1,024−12%/yr | −12%/yr | 0.71.9× | 0% | 1,010 in 2030−0.2%/yr |
Skin substitutes & wound grafts in every state, and its device makers · Every procedure market in Pennsylvania · Every state · Compare with New York
Integra LifeSciences leads with 25% of company spending on these surgeons in 2025, +3 pts on 2024.
In 2025, 31 companies reported engagement with Pennsylvania’s surgeons worth $657K in consulting, speaking, meals and travel tied to these products, about $22K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 13 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.